Third pharmaceutical company at SPAP

On 1 January 2025, iQone will become the third pharmaceutical company to join the Swiss Patient Access Program (SPAP). So far, Roche and AstraZeneca are partner companies of SPAP. As […]

Current status of SPAP – Swiss Patient Access Program

Current status of the SPAP project (Swiss Patient Access Program): The project has now been running for a little over a year The processes have been thoroughly tested and are […]

SGMO Curriculum – the new continuous education series in medical oncology

The SSMO, together with its cooperation partners, the Forum for Medical Education (FOMF) and the Swiss Academy of Medical Oncology (SAMO), offers a structured, application-oriented training programme for oncologists who […]

KVV/KLV revision – implementation difficulties: statement to the FDIA

The following letter was sent today (16 September 2024) to the FDIA by SSMO, SSH, SPOG, SAKK, the Swiss Cancer League, unimedsuisse and kosek: Herausforderungen bei der Anwendung von Artikel […]

OHI/OHCS revision – practical implications for doctors

On 1 January 2024, a comprehensive revision of the Ordinance on Health Insurance (OHI) and the FDHA Ordinance on Health Care Services (OHCS) came into force. On behalf of the […]

SSMO statement on KVV/KLV revision

The SSMO comments on KVV/KLV revision: Statement for the attention of the FOPH Article in the Swiss Medical Journal

Swiss Patient Access Program (SPAP)

The SSMO launched the Swiss Patient Access Program (SPAP) in 2023, as a follow-up project to the SPAP pilot. SPAP aims to: Avoid/reduce cases of hardship in processing Art. 71 […]